Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

Inclusion Criteria: * Over 19 years old * Type 2 diabetes mellitus * Patient who has been taking oral hypoglycemic agents for over 8 weeks * Agreement with written informed consent Exclusion Criteria: * Type 1 diabetes mellitus or secondary diabetes mellitus * Patients with complications of severe diabetes such as proliferative diabetic retinopathy * Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption * Patients with abnormal laboratory test results according to the protocol * Continuous or non-continuous treatment with insulin for over 7 days within 12 weeks prior to screening * History of treatment with corticosteroids within 4 weeks prior to screening